Cell-to-cell contact is one of the essential means of information transfer in metazoans. Few examples of such cell--cell contacts result in more drastic phenotypic changes than those between cytotoxic T-lymphocytes (CTL) and antigen presenting cells (APCs).^[@ref1]^ Naïve T-cells leave the thymus as small, featureless cells with minimal metabolism, but with a strong lymph node homing capacity, reliant on L-selectin and various integrins.^[@ref2]^ Each cell has a specific T-cell receptor (TCR) capable of recognizing a peptide presented by an APC on a major histocompatibility type-1 complex (MHC-I).^[@ref1]^ Upon recognition of its cognate peptide-MHC-I (pMHC), in combination with costimulatory signals copresented by the APC, massive and rapid phenotypic changes will transform the naïve CTL into a cell capable of killing any non-APCs displaying this cognate peptide on their MHC-I.^[@ref3]^ This is one of the major mechanisms by which tumors and virus-infected cells are routinely cleared from the body, and harnessing these traits underpins many of the cancer immunotherapies targeted to tumor neo-epitopes.^[@ref4]^

The binding of the TCR is sensitive. As few as one copy of a cognate peptide can instigate the signaling cascade *in vitro*.^[@ref5],[@ref6]^ It is also selective, as this recognition takes place in the context of 10 000's of copies of noncognate peptides on the same APC.^[@ref7],[@ref8]^ Even single amino acid substitutions are capable of curtailing,^[@ref9]^ or even abolishing, T-cell activation.^[@ref10]−[@ref12]^ A factor that complicates T-cell activation studies further is that there is no correlation between the binding strength *in vitro* and the strength of TCR-signaling that follows activation.^[@ref13]^ Less is known about the *in vivo* activation of T-cells.^[@ref14]^ The contacts between T-cells and APCs are, for example, more transient and dynamic in nature compared to those found *in vitro.*([@ref15]−[@ref18]) The lack of a defined starting point to these contacts complicates the study of T-cell activation kinetics, and methods allowing the study of early T-cell activation events with real-time control over activation *in vivo* are needed to study these processes.^[@ref14]^

Control over T-cell activation using protecting group strategies to achieve temporal control *in vitro* is an emerging field. Two approaches have been reported in which the ε-amines of lysine residues within either a helper T-cell epitope^[@ref19],[@ref20]^ or a cytotoxic T-cell epitope^[@ref12]^ are blocked with a protecting group. The addition of a deprotection reagent, such as UV-light to remove a nitroveratryl group,^[@ref19],[@ref20]^ or water-soluble phosphines to reduce azides to amines^[@ref21]^ provided this temporal control in the Petri dish. Arguably, the use of (UV) light as a trigger to activate T-cell epitopes has intrinsic limitations: poor tissue penetration even at higher wavelengths essentially prohibits systemic application of photocaged T-cell epitopes. On paper, bioorthogonal chemistry has no such tissue-penetrating limits; however, the chemistry needs to be effective (more so than the Staudinger reduction we applied previously) and all reagents able to penetrate all tissues. In this respect, the most versatile bioorthogonal chemistry developed to date for *in vivo* applications in terms of yield, speed, and side reactions comprises the inverse electron demand Diels--Alder reaction (IEDDA).^[@ref22]^ This \[4 + 2\] cycloaddition reaction occurs between an electron-poor diene (normally an *s*-tetrazine) and an electron-rich dienophile (most often a strained alkene). The tetrazine ligation between a tetrazine and a *trans*-cyclooctene was initially reported as an ultrafast bioorthogonal ligation reaction by the Fox group.^[@ref23]^

Recently, Versteegen et al.,^[@ref24]^ as well as Li et al.^[@ref25]^ and Agustin et al.^[@ref26]^ have shown that the IEDDA can also be used as a bioorthogonal deprotection reaction ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). In this variant of the IEDDA, the 4,5-dihydropyridazine, resulting from \[4 + 2\] cycloaddition of a tetrazine and a *trans*-cyclooctene (TCO) bearing a carbamate at the allylic position, tautomerizes to 1,4-dihydropyridazines. One of these 1,4-dihydropyridazines can then undergo elimination of a carbamate-linked biomolecule at the allylic position, resulting in the liberated biomolecule, CO~2~, and a cyclooctene-tetrazine elimination adduct. These adducts are different for each tetrazine used and can rearrange into the corresponding aromatic products, making it difficult to accurately perform toxicity studies. *In vivo* studies thus far have not shown any toxic side effects.^[@ref27]−[@ref29]^ Mechanistic investigations concerning this reaction are currently a field of interest.^[@ref30],[@ref31]^

![Design and synthesis of caged peptides. (a) Inverse electron-demand Diels--Alder (IEDDA) pyridazine elimination between a silent *trans*-cyclooctene-modified epitope and a tetrazine liberates antigenicity of the peptide. After initial cycloaddition, tautomerization and elimination results in the free lysine ε-amine upon which a T-cell can recognize the epitope again and become activated. (b) Synthesis of SIINFEK\[CCO\]L (**4**), SIINFEK\[TCO\]L (**5**), and SIINFEK\[mbTCO\]L (**7**). Reagents/conditions: (a) Fmoc SPPS from Fmoc-Leu-Wang; (b) methylsulfonylethyl succinimido-carbonate, DIPEA, NMP, rt; (c) TFA/H2O/TIPS (95:2.5:2.5), rt, 23%; (d) NHS-CCO (**2**), NHS-TCO (**3**), or NHS-mbTCO (**6**), DIPEA, DMF, rt; (e) ethanolamine, DMF, rt; (f) dioxane/MeOH/4 M NaOH (7.5:2.25:0.25), rt, 16% (**4**), 20% (**5**), 14% (**7**).](cb-2018-001554_0006){#fig1}

We here present a method based on this inverse electron demand Diels--Alder pyridazine elimination reaction that provides chemical control over the activation of T-cells *in vitro* and *in vivo* ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). The TCO protecting group was optimized for solubility and on-cell deprotection yield. The approach is generic based on the effectiveness for two separate epitopes and works with different T-cells *in vitro*, as well as *in vivo*.

Results and Discussion {#sec2}
======================

To determine whether TCO chemistry was amenable for *in vivo* T-cell activation and to compare its efficacy with that of our previously reported strategy based on Staudinger reduction,^[@ref12]^ we selected OVA~257--264~ (OT-I, SIINFEKL) as our model epitope, with modification on the crucial lysine ε-amino group having shown to block T-cell activation. The peptide sequence was synthesized using standard Fmoc solid phase peptide synthesis (SPPS) conditions followed by *N*-terminal protection with the methylsulfonylethyloxycarbonyl (MSc) group^[@ref32]^ to improve the solubility of the liberated peptide after acidic cleavage from the resin and to enable selective modification of the lysine ε-amine in the subsequent step ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b). From the purified intermediate (MSc-SIINFEKL, **1**), we synthesized *cis*- and (axial) *trans*-cyclooct-2-en-1-yl carbamate derivatives of SIINFEKL by reaction with the corresponding *N*-hydroxysuccinimide (NHS) esters (**2**, **3**) followed by deprotection under basic conditions of the MSc group to provide the *cis*- and *trans*-cyclooctene protected SIINFEKL-derivatives **4** and **5**. We also synthesized the bifunctional TCO reported by Rossin et al.^[@ref27]^ for modification of the lysine ε-amine. Peptide **1** was reacted with the NHS-carbonate of reagent **6** in the presence of its sterically hindered NHS-ester. Next, the latter was reacted with ethanolamine to install an extra polar moiety on the ring system. This resulted in a more soluble protected SIINFEKL (SIINFEK\[mbTCO\]L, **7**).

To establish the suitability of our caged peptides for on-cell uncaging, the binding affinity of the caged epitopes **4**, **5**, and **7** for K^b^-MHC-I were compared to the binding affinity of SIINFEKL using the temperature sensitive RMA-S cell line^[@ref33]^ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a). These experiments showed no affinity penalty resulting from the modification of Lys-7, in agreement with the observed solvent exposure of the ε-amine in the crystal structure of the complex.^[@ref34]^ The antibody 25D1, which is specific for SIINFEKL within the K^b^ MHC-I complex,^[@ref35]^ did not bind the caged epitopes on RMA-S cells, due to its known reliance on Lys-7 for recognition ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}a).^[@ref35]^ The T-cell hybridoma B3Z,^[@ref36]^ specific for the OVA~257--264~ epitope SIINFEKL, was also not activated by the caged variants **4**, **5**, and **7** when presented on dendritic cells either, up to 1 μM of peptide ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)).

![Optimization of *in vitro* deprotection of the *trans*-cyclooctene protected epitope SIINFEKL. (a) Binding affinity (MFI) of the caged epitopes, compared to SIINFEKL, to cell surface H2--K^b^ at low temperatures of the TAP deficient cell-line RMA-S. Analysis was performed with anti H2--K^b^ and H2--K^b^--SIINFEKL specific antibody (25-D1-APC). SIINFEK\[mbTCO\]L (**7̧** purple), CCO (**4**, green), and TCO (**5**, blue), SIINFEKL (red). (b,c) Deprotection of caged peptides (**4**, **5**, **7**) using DC2.4 cells as APCs and B3Z cells as T-cells. T-cell activation was compared to wild-type response (SIINFEKL; red) by measuring absorption (AU) of beta-galactosidase-directed CPRG hydrolysis. All experiments have been done twice in triplicate; error bars represent the standard error of the mean. (b) Deprotection of CCO (**4**, green), TCO (**5**, blue), and mbTCO (**7**, purple) in the presence of 50 μM 3,6-dimethyltetrazine (**8**) for 30 min and indicated peptide concentrations. (c) Deprotection of 100 nM mbTCO (**7**) after incubation with 50 μM **8** for the indicated times. After 1 min incubation, a significant (*p* = 0.04) T-cell response could already be detected.](cb-2018-001554_0001){#fig2}

We next determined to what extent and how fast our TCO-caged peptides could be deprotected *in vitro.* Caged epitopes **4**, **5**, and **7** were loaded on dendritic cells (DC2.4 cells^[@ref37]^) and incubated with 50 μM of 3,6-dimethyl-tetrazine (**8**) for 30 min ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}b). The B3Z T-cell response was measured as beta-galactosidase-directed CPRG (chlorophenol red-β-galactopyranoside) hydrolysis, which is in direct correlation with IL-2 promotor activity, due to its inclusion under the NFAT-promotor in the B3Z T-cell line.^[@ref36]^ At the highest concentration of peptide, no T-cell response was observed for the tetrazine-unreactive peptide **4**. However, tetrazine-reactive peptide **5** gave 42% ± 4.2% of the response observed for the wild type epitope. The mbTCO-modified peptide gave 82% ± 4.4% of the wildtype response at this time point. The response was also rapid: cells loaded with 100 nM of **7** yielded significant (p = 0.04) T-cell responses after 1 min of uncaging with 50 μM **8** ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}c). We also compared the stability of the TCO moiety for peptides **5** and **7** in full medium and FCS ([Figure S1](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)), revealing poor solubility for **5** and stability up to 4 h in FCS for **7**. For all further assays, we therefore continued with caged epitope **7** due to superior uncaging yield, ease of purification, and enhanced solubility.

The uncaging strategy was extrapolated to other antigen presenting cells (the D1 cell line^[@ref38]^ and bone-marrow derived dendritic cells, BM-DCs^[@ref39]^). Both these cell types showed significant and comparable levels of deprotection of the caged epitope (**7**) compared to DC2.4 under the same conditions (\>85% and \>48% T-cell activation compared to SIINFEKL, respectively ([Figure S2](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf))). Tetrazine **8** has been reported to be nontoxic *in vivo* up to 140 mg/kg (1.25 mmol/kg)^[@ref28]^ in mice. Negligible loss of cell viability was observed (up to 100 μM **8** ([Figure S3a,b](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf))), confirming this tolerance for APCs. The addition of serum had no influence on uncaging or T-cell response ([Figure S3c](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)).

The speed of the uncaging of mbTCO-SIINFEKL (**7**) was investigated using the recently reported asymmetric tetrazines,^[@ref30]^ which were shown to have improved kinetics due to a combination of electron donating and withdrawing substituents on the tetrazine ring. 3,6-Dipyrimidinyl-tetrazine (**9**; two EWGs) showed no detectable elimination, whereas 3-methyl-6-pyrimidinyl-tetrazine (**10**) and 3-hydroxyethyl-6-pyrimidinyl-tetrazine (**11**)^[@ref30]^ indeed showed improved uncaging rates and efficacy ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}**a**--**c**; verified using LC/MS analysis; [Figures S4, S5](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)) compared to **8**, with maximal T-cell activation already observed at the first (1 min) time point, while for **8** maximal T cell activation is reached at 30 min incubation. Additionally, the previously reported dextran-functionalized tetrazine (**12**), which has a reduced yield and uncaging speed compared to **8***in vitro*, but performs better *in vivo* due to reduced clearance,^[@ref27],[@ref40]^ was tested in our *in vitro* system. Tetrazine **12** showed similar concentration dependent behavior to that of **8** but slower uncaging speed, although linear in time. For later experiments, we focus on tetrazine **8**, **11**, and **12**, which also show negligible toxicity on APCs ([Figure S3a,b](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)).

![*In vitro* kinetics of uncaging of SIINFEK\[mbTCO\]L (**7**) using different tetrazines. (a) Structures of the four different tetrazines. (b/c) Deprotection of 100 nM **7** using DC2.4 cells as APCs and B3Z cells as T-cells. T-cell activation was compared to wild-type response (SIINFEKL; set at 1.0 normalized T-cell response) by measuring absorption (AU) of beta-galactosidase-directed CPRG hydrolysis. All experiments have been done twice in triplicate; error bars represent the standard deviation. (b) Uncaging of **7** with tetrazines **8**--**12** for 30 min at the indicated concentrations. (c) Deprotection reaction of **7** with tetrazines **8**--**12** at 10 μM of tetrazine at increasing incubation times. Tetrazine **9** blocks T-cell activation, and tetrazine **10** and **11** show improved uncaging speed compared to tetrazine **8**. Tetrazine **12** shows reduced uncaging speed and increases linearly. Relative T-cell response is normalized between SIINFEKL 100 nM response as 1.0 and no peptide background signal 0.0.](cb-2018-001554_0002){#fig3}

To assess whether the approach could be used for other key lysine residues as well as other MHC-I haplotypes, we used a second epitope in which T-cell recognition is dependent on a critical lysine, namely, the D^b^M~187--195~ peptide (NAITNAKII) from respiratory syncytial virus (RSV).^[@ref41]^ This virus is the main causative agent of respiratory failure in infants and responsible for significant mortality in the very young (\<2 years) and the elderly.^[@ref42]^ In C57BL/6 mice, M~187--195~ is a dominant epitope,^[@ref43]^ and a highly functional subdominant epitope in CB6F1 mice.^[@ref44]^ The peptide (sequence NAITNAKII) is a nonamer that binds the MHC-I haplotype D^b^, and the recognition by T-cells is critically dependent on Lys-193 recognition,^[@ref45]^ which we have previously shown is amenable to caging.^[@ref12]^ Synthesis of a mbTCO-caged variant of this peptide (NAITNAK\[mbTCO\]II, **13**) followed by a mixed splenocyte assay showed the same level of control over T-cell activation as seen for SIINFEKL/OT-I ([Figure S6](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)), suggesting application to lysine-cognate TCRs in general.

T-cell hybridomas (e.g., B3Z) lack some key hallmarks of native T-cell activation, due to their immortalized nature. For instance, hybridoma cells are in a continually dividing state, which makes them unsuitable for studying the switch from quiescence to activation, as this is marked by the switch from a nonproliferative to a highly proliferative state. Alterations in surface marker expression of these T-cells associated with this activation are also absent in these cell lines.^[@ref36]^ Naïve primary T-cells do allow the study of this activation switch, as they show these properties upon activation.^[@ref46]^ We therefore determined whether the approach was compatible with primary CTLs. Primary CTLs were isolated from OT-I mice, which has a homogeneous T-cell population selective for the SIINFEKL-epitope.^[@ref46]^ CD62L and CD69 are the first markers that show changes in cell-surface expression levels upon T-cell activation *in vitro*.^[@ref2],[@ref47],[@ref48]^ We therefore quantified changes in surface expression levels of these early markers, and the induction of proliferation, upon IEDDA-deprotection on primary naïve CTLs.

Analysis of early activation markers showed similar kinetics of CD62L downregulation and CD69 upregulation upon pulsing with SIINFEKL or upon preloading with **7**, followed by tetrazine-mediated uncaging with **11** ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). The uncaged **7** shows a slight delay for both markers; however, after 180 min a similar level of early markers is reached. The histograms ([Figure S7a,b](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)) of each time point are also similar, indicating no increase in the heterogeneity of activation. These early markers demonstrate that the activation of T-cells using a caged epitope shows a similar profile of activation upon the addition of tetrazine **11** compared to the natural epitope. The caged epitope (**7**, up to 100 pM) and tetrazine **11** (10 μM) induced no background proliferation ([Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)). The addition of **11** to **7**-pulsed OT-I cells induced T-cell proliferation ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b). The addition of **11** to SIINFEKL changed the proliferation pattern. These differences were assigned to earlier observed sensitivity of these cells; even slight changes in environment have an effect on activation/proliferation.

![Primary T-cell (OT-I) proliferation and the early T-cell activation of SIINFEK\[mbTCO\]L (**7**) can be controlled by tetrazine elimination. (a) Detection (MFI) of early activation markers upon deprotection of **7** (100 pM) with **11** (10 μM) using primary T-cells (OT-I). Early activation markers CD62L and CD69 were compared to wild-type response (SIINFEKL, 100 pM) by using fluorescent antibodies (CD62L-APC and CD69-PE, respectively). Data of three individual experiments with SD, normalized between highest signal obtained and zero fluorescence intensity. (b) OT-I proliferation at day 3 after incubation with 100 pM of peptide (SIINFEKL or **7**) and 10 μM of tetrazine **11**; representative figure of experiment performed twice.](cb-2018-001554_0003){#fig4}

Encouraged by these *ex vivo* results, we set out to translate the chemical control over early activation events, CD62L shedding and CD69 upregulation, and T-cell proliferation from an *in vitro* to *in vivo* setting. For this, OT-I cells were adoptively transferred on day −1 i.v. in the lateral tail vein, allowing distribution of the cells throughout the body,^[@ref49]^ followed by tail base s.c. injection of **7** at day 0. Tetrazine **11** was injected subcutaneously (s.c.) in the right flank above the right inguinal lymph node (iLN) and incubated for 1, 2, or 3 h. Afterward, mice were sacrificed, and iLNs were extracted. Cells were stained and analyzed by FACS. At 3 h, 70% of CD8α^+^-CD45.1^+^ T-cells were double positive (CD62L^--^ and CD69^+^) in the right inguinal lymph node (iLN) compared to 17% in the left ([Figure S9](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf)).

On the basis of these initial results, the experiment was repeated with three mice per group at 3 h of tetrazine incubation ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a,b). Interestingly, even injecting only the caged peptide **7** already resulted in significant down- and upregulation of CD62L and CD69, respectively (*p* = 0.0004 and *p* \< 0.0002), indicating the presence of an *in vivo* mechanism for T-cell activation by antigens for which a TCR has low affinity. However, when tetrazine **11** was also injected, a significant difference was detected for CD62L compared to protected peptide **7** alone (*p* \< 0.05). Dextran tetrazine **12** induced significant shifts for both markers. Furthermore, significant differences were observed between left and right iLN for both markers (CD62L *p* \< 0.05 and CD69 *p* \< 0.01). When assessing both markers in combination as a more robust method for selecting activated T-cells,^[@ref19]^ left over right differences became clearer. A similar percentage of double activated T-cells were observed in the right iLN (84.7% ± 6.9% of CD8α^+^-CD45.1^+^ T-cells; compared to 87.3% ± 1.3% for SIINFEKL in the right iLN), whereas only 43.1% ± 12% cells showed activation of both markers in the contralateral iLN. The dextran-functionalized tetrazine **12** has been reported to have slower clearing properties,^[@ref27]^ and therefore we hypothesize that this slower diffusion time explains the increased control over localized activation. These results show the regioselective potential of the approach.

![*In vivo* activation and proliferation of OT-I cells after local tail base injection of SIINFEK\[mbTCO\]L (**7**) and subsequent injection of tetrazine **8**, **11**, or **12**. (a,b) CD62L and CD69 cell surface appearances were measured on OT-I T-cells using fluorescent antibodies: CD62L-APC and CD69-PE. When CD62L was decreased and CD69 was increased, the T-cells were qualified as activated. Mice were injected in the tail base area on both sides of the tail with a total amount of 10 nmol peptide (**7** or SIINFEKL) and later injected with 100 nmol tetrazine or PBS only s.c. in the right flank right above the right iLN. (a) Activation of right and left iLN represented as MFI of CD62L and CD69, respectively. Three mice per experimental group and two for each control group. Dots represent individual lymph nodes. (b) Bar chart representation of percentage of OT-I cells fully activated, positive for CD69 and negative for CD62L, with error bars as SD. There is a significant difference between **7** and **7** + **12** with *p* \< 0.0002. There is even a significant difference between the left and right iLN for tetrazine dextran (**12**) of *p* \< 0.01. *P* values were determined using an unpaired *t* test without assuming consistent SD. (c,d) After adoptive transfer of CSFE labeled OT-I T-cells, mice were injected with 10 nmol of **7** or SIINFEKL in the tail base area followed by an injection of 1 μmol **8** or PBS control after 30 min. (c) Histograms of the OT-I T-cell proliferation after 3 days. (d) Percentage of divided OT-I T-cells of total lymphocytes (data of two mice per group, represented with standard error of the mean).](cb-2018-001554_0004){#fig5}

To correlate these early activation events observed *in vivo* to full activation, the proliferation of OT-I T-cells was studied after 3 days. CFSE-labeled OT-I T-cells^[@ref46]^ were adoptively transferred in recipient C57BL/6 mice on day −1. On day 0, the mice were either injected with mbTCO SIINFEKL (**7**) or SIINFEKL in the tail base. After 3 days, the amount of T-cell proliferation was assessed by flow cytometry through CFSE-dilution ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c).^[@ref50]^ Under these conditions, compound **7** induced very low levels of proliferation of OT-I CTLs, and upon injection with tetrazine **8**, CTL proliferation was induced similar to SIINFEKL (3.1% ± 0.11% vs 4.4% ± 0.05% divided OT-I of total lymphocytes; [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}d).

Conclusion {#sec3}
----------

In our attempts to develop a methodology that allowed chemical control over T-cell activation, we have here demonstrated that the IEDDA-pyridazine elimination reaction can be used to exert chemical control over T-cell activation *in vitro* and *in vivo.* The technique complements other bio-orthogonal deprotection strategies *in vitro*, such as palladium-mediated reductions^[@ref51],[@ref52]^ or Staudinger-based chemistry.^[@ref21]^ Without the presence of a tetrazine, the lysine-caged epitopes show no T-cell receptor activation while MHC-I binding was not affected. Upon deprotection, T-cell receptor activation was restored. The lysine cage was implemented in two different epitopes, suggesting a generic application to lysine-sensitive TCRs.

*In vivo*, chemical deprotection of a caged peptide epitope could be achieved selectively 3 h post epitope injection. Using this decaging approach, local early activation of T-cells could be detected by quantifying cell surface expression of two early markers of T-cell activation, CD69 and CD62L, showing significant T-cell activation with tetrazine **12**. Furthermore, *in vivo* results showed very similar T-cell proliferation potency upon decaging epitope **7** compared to the natural epitope, whereas the caged epitope showed no proliferation by itself. Selective activation was achieved through localized peptide and tetrazine injections in the tail base. Systemic administration would be more beneficial for clinical translation; however, systemic T-cell activation can cause the so-called cytokine release syndrome (CRS). CRS occurs when a large number of immune cells are activated and release inflammatory cytokines, potentially causing death.^[@ref53]^ By combining this uncaging technique with injectable tetrazine-hydrogels^[@ref29]^ or antibody-epitope conjugates,^[@ref27]^ the activation of T-cells could be controlled more precisely in future experiments. This can provide new angles to the study of CTL activation *in vivo*, analogous to that which has been achieved *in vitro* using photo-^[@ref19],[@ref20],[@ref54]^ and chemo^[@ref12]^-deprotection. We foresee that this mild, fast deprotection chemistry will be a valuable addition to the study of T-cell-APC interactions and will ultimately lead to spatiotemporal control of T-cell activation *in vivo*.

Methods {#sec4}
=======

A detailed description of the methods is provided in the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acschembio.8b00155](http://pubs.acs.org/doi/abs/10.1021/acschembio.8b00155).Experimental procedures and methods, characterization data, supporting figures ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acschembio.8b00155/suppl_file/cb8b00155_si_001.pdf))
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